|
Gene: SGK494 |
Gene summary for SGK494 |
Gene summary. |
Gene information | Species | Human | Gene symbol | SGK494 | Gene ID | 124923 |
Gene name | ribosomal protein S6 kinase related | |
Gene Alias | SGK494 | |
Cytomap | 17q11.2 | |
Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | L7N484 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
124923 | SGK494 | HCC1_Meng | Human | Liver | HCC | 1.06e-09 | 5.55e-04 | 0.0246 |
124923 | SGK494 | HCC1 | Human | Liver | HCC | 3.74e-03 | 1.99e+00 | 0.5336 |
124923 | SGK494 | HCC2 | Human | Liver | HCC | 1.94e-11 | 1.39e+00 | 0.5341 |
124923 | SGK494 | HCC5 | Human | Liver | HCC | 1.80e-09 | 7.76e-01 | 0.4932 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Liver | HCC: Hepatocellular carcinoma | |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SGK494 | SNV | Missense_Mutation | rs759443821 | c.532N>T | p.Arg178Trp | p.R178W | protein_coding | deleterious(0.02) | benign(0.005) | TCGA-A7-A0CD-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
SGK494 | SNV | Missense_Mutation | novel | c.989G>A | p.Gly330Asp | p.G330D | protein_coding | tolerated(0.43) | benign(0.015) | TCGA-A8-A09C-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
SGK494 | SNV | Missense_Mutation | c.853N>A | p.Asp285Asn | p.D285N | protein_coding | deleterious(0.03) | probably_damaging(1) | TCGA-C5-A1BQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | CR | ||
SGK494 | SNV | Missense_Mutation | novel | c.461A>T | p.Glu154Val | p.E154V | protein_coding | deleterious(0) | benign(0.296) | TCGA-C5-A7UI-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
SGK494 | SNV | Missense_Mutation | c.215N>T | p.Ala72Val | p.A72V | protein_coding | tolerated(0.07) | benign(0.007) | TCGA-Q1-A5R3-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PR | ||
SGK494 | SNV | Missense_Mutation | novel | c.250N>T | p.Pro84Ser | p.P84S | protein_coding | tolerated(0.09) | probably_damaging(0.991) | TCGA-AA-3811-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD | |
SGK494 | SNV | Missense_Mutation | c.412G>A | p.Val138Met | p.V138M | protein_coding | tolerated(0.24) | benign(0.039) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | ||
SGK494 | SNV | Missense_Mutation | rs777948679 | c.773N>T | p.Ala258Val | p.A258V | protein_coding | tolerated(0.1) | benign(0.007) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
SGK494 | SNV | Missense_Mutation | c.34A>G | p.Thr12Ala | p.T12A | protein_coding | tolerated_low_confidence(0.76) | benign(0.017) | TCGA-CK-5913-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
SGK494 | SNV | Missense_Mutation | c.419A>C | p.Lys140Thr | p.K140T | protein_coding | deleterious(0) | possibly_damaging(0.537) | TCGA-CM-5861-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |